Susquehanna Fundamental Investments LLC Invests $543,000 in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Susquehanna Fundamental Investments LLC acquired a new stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 39,093 shares of the company’s stock, valued at approximately $543,000. Susquehanna Fundamental Investments LLC owned approximately 0.08% of Tyra Biosciences as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Barclays PLC boosted its stake in shares of Tyra Biosciences by 200.5% during the third quarter. Barclays PLC now owns 37,625 shares of the company’s stock valued at $884,000 after purchasing an additional 25,106 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Tyra Biosciences by 1.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock worth $8,667,000 after buying an additional 3,896 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Tyra Biosciences during the 4th quarter worth approximately $149,000. Rhumbline Advisers increased its position in Tyra Biosciences by 4.1% in the 4th quarter. Rhumbline Advisers now owns 26,202 shares of the company’s stock valued at $364,000 after acquiring an additional 1,027 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Tyra Biosciences by 5.2% during the fourth quarter. Bank of New York Mellon Corp now owns 45,007 shares of the company’s stock valued at $626,000 after acquiring an additional 2,221 shares during the last quarter. Institutional investors own 84.14% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Monday, March 31st. Wedbush reissued an “outperform” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research note on Friday, March 28th. Finally, UBS Group began coverage on Tyra Biosciences in a research note on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price objective on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $30.83.

Insider Buying and Selling at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 5,401 shares of the business’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $13.76, for a total value of $74,317.76. Following the completion of the sale, the director now directly owns 443,885 shares of the company’s stock, valued at $6,107,857.60. The trade was a 1.20 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 15.40% of the company’s stock.

Tyra Biosciences Price Performance

Shares of Tyra Biosciences stock opened at $10.86 on Friday. The firm has a market cap of $576.56 million, a price-to-earnings ratio of -6.75 and a beta of 1.19. The stock’s 50-day moving average is $9.80 and its 200 day moving average is $13.82. Tyra Biosciences, Inc. has a one year low of $6.42 and a one year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.05. On average, sell-side analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.